@Hooda
Alcohol, Drugs and Addictive Behaviours
In the choice of treatment, WHO recommends OAMT to be used for most patients as the intervention with strongest evidence of effectiveness for variety of outcomes. Medicinal products containing two or more active ingredients are regarded as combinations in the ATC classification system and given different ATC codes from the product with a single component (one active ingredient). This will often give several classification alternatives and the main indication is decided by the WHO International Working Group for Drug Statistics Methodology on the basis of available literature and a qualified assumption of the most prevalent indication worldwide. The challenge occurs when a medicinal product (same strength and route of administration) is approved and used for two or more equally important indications, and the main therapeutic use differs from one country to another. For example, low strength finasteride tablets used for treatment of baldness are classified under D11AX Other dermatologicals and the high strength tablets used for benign prostatic hyperplasia (BPH) are classified under G04C Drugs used in BPH.
- While some 64 million people globally are estimated to live with drug use disorders, access to treatment remains very limited, with less than 10% having access to it.
- Such drugs are usually only given one code and this may be a problem for users in countries where other uses are predominant.
- Meeting of technical experts on public health responses to cannabis use
- Medium priority pathogens include Group A and B Streptococci (both new to the 2024 list), Streptococcus pneumoniae, and Haemophilus influenzae, which present a high disease burden.
- It presents a range of perspectives on how current challenges impact the manufacture, prescribing and access of medicines throughout the world and introduces newly-released guidance documents.
- The challenge occurs when a medicinal product (same strength and route of administration) is approved and used for two or more equally important indications, and the main therapeutic use differs from one country to another.
Defined Daily Dose (DDD)
In Hanoi, WHO’s collaboration provides a rosy picture of health Digital version of Essential Medicines list (eEML) launched Promoting rational use of medicines Strengthening access to essential medicines
Guidelines for identification and management of substance use and substance use disorders in pregnancy
The Framework builds on WHO’s Global health sector strategies and aligns with the Sustainable Development Goals and the Global Action Plan on Antimicrobial Resistance. “Drug resistance threatens decades of progress in HIV, hepatitis and STI control. It emphasizes antimicrobial stewardship, stronger surveillance systems, and equitable access to high-quality prevention, diagnosis and treatment services for HIV, hepatitis B and C and STIs. This feedback helps WHO develop high-quality guidelines that reflect diverse perspectives and respond to the needs of communities worldwide. To ensure transparency and inclusivity, WHO invites members of the public and interested organizations to review the biographies of the GDG members and provide feedback. GDG members were selected by WHO technical staff based on their technical expertise, their role as end-users (e.g., programme managers and healthcare providers), and their representation of affected communities.
ATC 3rd& 4th levels
Equal access and the reliable supply of medicines is anongoing goal of WHO and global health delivery systems, the achievement ofwhich is hampered by several factors. Working to increase access to essentialpharmaceuticals while limiting the spread of falsified products is at the heart of WHO’s global strategy on medicines. Quality-assured, safe and effective medicines, vaccines and medicaldevices are fundamental to a functioning health system. Drug dependence treatment and care in the Republic of Serbia Meeting of technical experts on public health responses to cannabis use The publication was invited by resolution 58/5 of the Commission on Narcotic Drugs entitled “Supporting the collaboration of public health and justice…
Both publications are updated annually and available electronically and in hard copies. The ATC/DDD guidelines and the Index were both published for the first time in the current format in 1990. This Centre is located at the Norwegian Institute of Public Health (NIPH) and the main activities of the Centre are drawn up in an agreement between the WHO Headquarters and the Government of Norway. There are also international differences between PDDs, which can be up to four or five fold higher/lower. When there is a substantial discrepancy between the PDD and the DDD, it is important to take this into consideration when evaluating and interpreting drug utilization figures.
It is crucial that people with opioid dependence and those at risk of opioid overdose have access to prevention, harm reduction, treatment, and care, which are Drug Overdose Facts of good quality, affordable, ethical and evidence based. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR). These include opioid agonist maintenance treatment (or OAMT) with medicines such as methadone and buprenorphine, pharmacological treatment with opioid antagonists (such as naltrexone) as well as psychosocial support.
Guidelines
In the guidelines, WHO recommends the use of a range of treatment options for opioid dependence. Since 1977, WHO has maintained a list of essentialmedicines as a means to promote health equity around the world. At the same time, antimicrobial resistance is challenging the effectiveness of many commonly used medicines in one of the most concerning threats to global health today. Since then there have been incredible advances in drugs for a wide range of health concerns including disease, mental health and other conditions. WHO updates guidelines on opioid dependence treatment and overdose prevention The UNGASS marked a shift in the overall drug policy discourse to highlight the public health and human rights dimensions of the world drug problem and to achieve a better balance between supply reduction and public health measures.
Drug overdose: a film about life
In 2022, approximately 60 million people globally engaged in non-medical opioid use, including the use of drugs like heroin, morphine, codeine, fentanyl, methadone, tramadol, and other similar substances. Currently, WHO is convening a guideline development group (GDG) for update of both guidelines with an aim to improve availability and access to treatment of opioid dependence and reduce the number of deaths from opioid overdose by providing evidence-based recommendations on the psychosocially assisted pharmacological treatment and interventions on prevention and management of opioid overdose. WHO announces development of updated guidelines for the psychosocially assisted pharmacological treatment of opioid dependence and community management of opioid overdose Opioid agonist maintenance treatment (OAMT) for people with opioid dependence is proven to be safe and effective in addressing a broad range of health…
Honduras: Listado Nacional de Medicamentos Esenciales LNME 2023 (Spanish)
These pathogens require increased attention, especially in vulnerable populations including paediatric and elderly populations, particularly in resource-limited settings. Medium priority pathogens include Group A and B Streptococci (both new to the 2024 list), Streptococcus pneumoniae, and Haemophilus influenzae, which present a high disease burden. High priority pathogens, such as Salmonella and Shigella, are of particularly high burden in low- and middle-income countries, along with Pseudomonas aeruginosa and Staphylococcus aureus, which pose significant challenges in healthcare settings.
- 1st WHO Forum on alcohol, drugs and addictive behaviours
- Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development…
- Access to appropriate medications is shown to have substantial impacts on community health and the related economic indicators.
For example, calcium channel blockers are classified in the pharmacological group C08 (see classification of verapamil below), which avoids specifying whether the main indication is coronary heart disease or hypertension. Medicinal substances are classified according to their main therapeutic use on the basic principle of only one ATC code for each medicinal product (as defined by route of administration and in some cases strength). The system has fourteen main anatomical or pharmacological groups (1st level).
WHO recommends that essential medicines, including those that are controlled, be available to all patients at all times at a price that the individual… Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development… More than 36 million years of healthy life loss (DALY) were attributable to drug use in 2019. Psychoactive drugs are substances that, when taken in or administered into one’s system, affect mental processes, e.g. perception, consciousness, cognition or mood and emotions. English and Spanish versions of the publications are available.
Revisions of the Essential Medicines lists
AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of disease spread, illness and deaths. “Together, we can preserve the effectiveness of life-saving antimicrobial drugs and accelerate progress toward ending these epidemics.” The new framework proposes a unified approach to prevent the emergence and spread of resistance and reduce its impact through integrated, people-centred strategies. Without urgent, coordinated action, it could lead to increased new infections and treatment failures and higher preventable morbidity and mortality, and undermine global elimination goals. Drug resistance is a major challenge to prevention and treatment efforts. Such drugs are usually only given one code and this may be a problem for users in countries where other uses are predominant.
1st WHO Forum on alcohol, drugs and addictive behaviours 2nd WHO Forum on alcohol, drugs and addictive behaviours These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which… Cannabis is globally the most commonly used psychoactive substance under international control.
The first edition was published in 2013 and summarized the evidence of drug use prevention at the global level. WHO drug information provides an overview of topics of current relevance relating to drug development and regulation. The Global status report on alcohol and health and treatment of substance use disorders presents a comprehensive overview of alcohol consumption, alcohol-related…
The World Medicines Situation 2011- Access to controlled medicines, 3rd edition
The fact that third-generation cephalosporin-resistant Enterobacterales are listed as a standalone item within the critical priority category emphasizes their burden and need for targeted interventions, especially in low- and middle-income countries. Changes between the 2017 and 2024 lists “Antimicrobial resistance jeopardizes our ability to effectively treat high burden infections, such as tuberculosis, leading to severe illness and increased mortality rates,” said Dr Jérôme Salomon, WHO’s Assistant Director-General for Universal Health Coverage, Communicable and Noncommunicable Diseases.
Drugs (psychoactive)
WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Guidelines and recommendations concerning medicines, biologicals, vaccines, medical devices, herbals and related products WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers. It is estimated that worldwide there are almost 14.8 million people who inject drugs, of whom 15.2% live with HIV and 38.8% – with hepatitis C. Production, distribution, sale or non-medical use of many psychoactive drugs is either controlled or prohibited outside legally sanctioned channels by law. Changes to the index are made annually and a cumulative list including all ATC and DDD alterations made since 1982 is available here .
About 296 million people aged had used psychoactive drugs in 2021 and about 39.5 million people are estimated to be affected by drug use disorders (harmful pattern of drug use or drug dependence). Psychoactive drugs have different degrees of restriction of availability, depending on their risks to health and therapeutic usefulness, and classified according to a hierarchy of schedules at both national and international levels. This is crucial for mitigating AMR’s impact on public health and the economy.





